American Century Companies Inc. increased its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 33.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,144,526 shares of the company’s stock after acquiring an additional 284,266 shares during the period. American Century Companies Inc. owned about 0.92% of Ionis Pharmaceuticals worth $58,027,000 at the end of the most recent reporting period.
Other hedge funds have also recently modified their holdings of the company. Parallel Advisors LLC grew its position in Ionis Pharmaceuticals by 62.8% during the 2nd quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock worth $109,000 after acquiring an additional 800 shares during the last quarter. Hanseatic Management Services Inc. grew its position in shares of Ionis Pharmaceuticals by 1.2% in the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock valued at $177,000 after buying an additional 41 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Ionis Pharmaceuticals by 9.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after buying an additional 311 shares during the last quarter. WFG Advisors LP grew its position in shares of Ionis Pharmaceuticals by 77.2% in the 2nd quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock valued at $193,000 after buying an additional 1,655 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in shares of Ionis Pharmaceuticals in the 2nd quarter valued at about $222,000. Institutional investors and hedge funds own 89.05% of the company’s stock.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) opened at $55.88 on Friday. The firm has a market capitalization of $6,973.60, a P/E ratio of 372.53 and a beta of 2.90. Ionis Pharmaceuticals, Inc. has a 52 week low of $37.26 and a 52 week high of $65.51. The company has a debt-to-equity ratio of 1.50, a quick ratio of 5.00 and a current ratio of 6.25.
A number of research firms have commented on IONS. Stifel Nicolaus upped their price target on Ionis Pharmaceuticals from $42.00 to $50.00 and gave the company a “hold” rating in a research report on Wednesday, August 9th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research report on Wednesday, July 26th. BMO Capital Markets upped their price target on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday. Evercore ISI initiated coverage on Ionis Pharmaceuticals in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $65.00 price objective on the stock. Finally, Zacks Investment Research downgraded Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company. Ionis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $50.31.
TRADEMARK VIOLATION WARNING: This story was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://ledgergazette.com/2017/11/12/american-century-companies-inc-raises-position-in-ionis-pharmaceuticals-inc-ions.html.
In other Ionis Pharmaceuticals news, SVP Patrick R. O’neil sold 1,000 shares of the stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $55.00, for a total transaction of $55,000.00. Following the completion of the transaction, the senior vice president now directly owns 10,633 shares of the company’s stock, valued at $584,815. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Chairman Stanley T. Crooke sold 27,500 shares of the stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $52.89, for a total value of $1,454,475.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 98,636 shares of company stock valued at $5,723,915. Company insiders own 2.13% of the company’s stock.
Ionis Pharmaceuticals Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.